Population pharmacokinetics and pharmacodynamics of investigational regimens' drugs in the TB-PRACTECAL clinical trial (the PRACTECAL-PKPD study): a prospective nested study protocol in a randomised controlled trial. by Nyang'wa, Bern-Thomas et al.
1Nyang'wa B- T, et al. BMJ Open 2021;11:e047185. doi:10.1136/bmjopen-2020-047185
Open access 
Population pharmacokinetics and 
pharmacodynamics of investigational 
regimens’ drugs in the TB- PRACTECAL 
clinical trial (the PRACTECAL- PKPD 
study): a prospective nested study 
protocol in a randomised controlled trial
Bern- Thomas Nyang'wa   ,1,2 Frank Kloprogge   ,3 David A.J. Moore,2 
Amaya Bustinduy,2 Ilaria Motta,1 Catherine Berry,1 Geraint R Davies4
To cite: Nyang'wa B- T, 
Kloprogge F, Moore DA.J, et al.  
Population pharmacokinetics 
and pharmacodynamics of 
investigational regimens’ drugs 
in the TB- PRACTECAL clinical 
trial (the PRACTECAL- PKPD 
study): a prospective nested 
study protocol in a randomised 
controlled trial. BMJ Open 
2021;11:e047185. doi:10.1136/
bmjopen-2020-047185
 ► Prepublication history for 
this paper is available online. 
To view these files, please visit 
the journal online (http:// dx. doi. 
org/ 10. 1136/ bmjopen- 2020- 
047185).
Received 23 November 2020
Accepted 08 July 2021
For numbered affiliations see 
end of article.
Correspondence to
Dr Bern- Thomas Nyang'wa;  
 bern- thomas. nyangwa@ lshtm. 
ac. uk
Protocol
© Author(s) (or their 
employer(s)) 2021. Re- use 
permitted under CC BY- NC. No 
commercial re- use. See rights 
and permissions. Published by 
BMJ.
ABSTRACT
Introduction Drug- resistant tuberculosis (TB) remains 
a global health threat, with little over 50% of patients 
successfully treated. Novel regimens like the ones being 
studied in the TB- PRACTECAL trial are urgently needed. 
Understanding anti- TB drug exposures could explain the 
success or failure of these trial regimens. We aim to study 
the relationship between the patients’ exposure to anti- TB 
drugs in TB- PRACTECAL investigational regimens and their 
treatment outcomes.
Methods and analysis Adults with multidrug- resistant 
TB randomised to investigational regimens in TB- 
PRACTECAL will be recruited to a nested pharmacokinetic- 
pharmacodynamic (PKPD) study. Venous blood samples 
will be collected at 0, 2 and 23 hours postdose on day 
1 and 0, 6.5 and 23 hours postdose during week 8 to 
quantify drug concentrations in plasma. Trough samples 
will be collected during week 12, 16, 20 and 24 visits. 
Opportunistic samples will be collected during weeks 
32 and 72. Drug concentrations will be quantified using 
liquid chromatography- tandem mass spectrometry. 
Sputum samples will be collected at baseline, monthly to 
week 24 and then every 2 months to week 108 for MICs 
and bacillary load quantification. Full blood count, urea 
and electrolytes, liver function tests, lipase, ECGs and 
ophthalmology examinations will be conducted at least 
monthly during treatment.
PK and PKPD models will be developed for each drug with 
nonlinear mixed effects methods. Optimal dosing will be 
investigated using Monte- Carlo simulations.
Ethics and dissemination The study has been approved 
by the Médecins sans Frontières (MSF) Ethics Review 
Board, the LSHTM Ethics Committee, the Belarus RSPCPT 
ethics committee and PharmaEthics and the University of 
Witwatersrand Human Research ethics committee in South 
Africa. Written informed consent will be obtained from all 
participants. The study results will be shared with public 
health authorities, presented at scientific conferences and 
published in a peer- reviewed journal.
Trial registration number NCT04081077; Pre-results.
INTRODUCTION
Tuberculosis (TB) remains the deadliest 
infectious disease in the world, killing an esti-
mated 1.4 million people of the 10 million 
people who developed the disease in 2019. 
TB that is resistant to the most powerful 
anti- TB drug, rifampicin resistant (RR)- TB, 
caused disease in half a million people repre-
senting 5% of all TB and yet is estimated to 
have caused death in 15% (182 000).1 WHO 
currently recommends use of either a shorter 
treatment regimen (9–12 months) or a longer 
regimen lasting up to 20 months for the treat-
ment of multidrug- resistant (MDR)/RR- TB 
depending on prior exposure or proven resis-
tance to second line anti- TB drugs. A 6–9 
months regimen consisting of bedaquiline 
(B), pretomanid (Pa) and linezolid (Lzd) 
which was used in the NiX- TB study2 has 
been recommended for use in operational 
research.3
PRAgmatic Clinical Trial for a more 
Effective, Concise And Less toxic MDR- TB 
Strengths and limitations of this study
 ► This is the first study that prospectively evaluates 
the pharmacokinetic (PK) and PK- pharmacodynamic 
properties of three novel exclusively oral, short 
course multidrug- resistant- tuberculosis treatments; 
bedaquiline, pretomanid, linezolid in absence and 
presence of either moxifloxacin or clofazimine.
 ► The study is including participants from key popula-
tions (HIV positive and on antiretrovirals) as well as 
in ethnically diverse populations (South Africa and 
Belarus).
 ► Being a nested study, the sample size is mainly de-
termined by the parent study.
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regimens (TB- PRACTECAL) is a multicentre, open 
label, phase 2–3 randomised controlled trial evaluating 
6 months duration, exclusively oral regimens containing 
bedaquiline, pretomanid, linezolid±moxifloxacin (Mfx) 
or clofazimine (Cfz) for the treatment of microbiologically 
confirmed pulmonary RR- TB. In the TB- PRACTECAL 
trial, B is dosed at 400 mg daily for 2 weeks and then 200 
mg three times a week for 22 weeks. Pretomanid is dosed 
at 200 mg daily for 24 weeks. Linezolid is dosed at 600 mg 
daily for 16 weeks and then reduced to 300 mg daily for 8 
weeks. Mfx is given at 400 mg daily for 24 weeks and Cfz is 
dosed at 100 mg daily for body weight above 33 kg and 50 
mg daily below 33 kg for 24 weeks.
A cumulating body of evidence has shown that anti- TB 
drug exposure especially in HIV positive patients varies 
significantly.4Moreover, low- drug concentrations are 
linked to poor outcomes,5 particularly microbiological 
failure.6 Identifying the optimal dose and duration of 
drugs such as linezolid in treating RR- TB remains a global 
research priority.3
If the TB- PRACTECAL trial identifies successful 
regimens, the PRACTECAL- pharmacokinetic- 
pharmacodynamic (PKPD) substudy will provide explan-
atory evidence to why the tested regimens at the chosen 
doses and administration scenario are efficacious. And 
if the regimens have not been shown to be non- inferior, 
allow the understanding of whether variability of partic-
ular drug exposures could have played a part in the 
efficacy or safety outcomes and make appropriate recom-
mendations for further research.7
We; therefore, aim to study the relationship 
between the patients’ exposure to anti- TB drugs in the 




The Fisher Information Matrix (FIM)8 was used to opti-
mise a venous blood sampling design that supports PK 
model development in that expected PK model param-
eter estimate precision will be ≤20%.
Identification of prior information
A structured literature search was done in Medline, 
Embase and PubMed databases and relevant conferences 
in August 2017, with the following search terms (popu-
lation pharmacokinetics AND drug_name) to identify 
published population PK models. The search yielded 5, 
0, 3, 1 and 5 relevant papers for linezolid,9–13 pretomanid, 
bedaquiline,14 Cfz15 and Mfx,16–20 respectively. Authors 
were contacted when full text articles were not accessible 
and drug developers were contacted with the request to 
share unpublished models.21 Where more than one suit-
able PK model was available, the following hierarchically 
listed criteria were used to select a suitable model to be 
used for design optimisation: study population (MDR- 
TB, TB, non- TB patients or healthy subjects), original PK 
study sample size (larger sample sizes preferred), and a 
critical appraisal of the publications including whether 
the authors reported enough parameters to allow for 
parameterisation of the model.
Identification and definition of constraints
The FIM was maximised given a series of design constrains. 
First, samples could only be collected on scheduled visits 
with planned laboratory sample collection as per main 
study protocol. Second, venous plasma samples could 
only be scheduled during day nurse working and labo-
ratory opening hours in order to warrant access to staff, 
centrifuges and freezers. Lastly, the sampling intervals 
could not be shorter than 15 min in order to warrant that 
the protocol is executable by clinical and laboratory staff.
Sampling schedule optimisation
ED design optimisation with uncertainty on clearance 
estimates, using PopED; an R- package22 (V.0.3.2), was 
used to simultaneously optimise a venous blood sampling 
schedule for pretomanid21 and linezolid13 in first instance. 
Subsequently, bedaquiline,23 Cfz15 and Mfx19 expected 
elimination clearance estimates were evaluated given the 
optimal venous plasma sampling designs for pretomanid 
and linezolid. The two- step approach was chosen due to 
the distinctly different PK profiles of bedaquiline, Cfz 
and Mfx, with an elimination phase outside the 24- hour 
dosing schedule, when compared with pretomanid and 
linezolid.
Design evaluation
The optimal venous blood sampling schedule was subse-
quently evaluated for each study drug using the stochastic 
simulation and estimation (SSE) function of PsN24 with 
NONMEM (V.7.3). The optimal evaluated design was for 
240 patients sampled at day 0 (0, 2, 23 hours), week 8 
(0, 6.5, 23 hours), trough at weeks 12, 16, 20 and 24 and 
opportunistic at week 32 and 72. The expected relative 




What is the relationship between the patients’ exposure 
to anti- TB drugs in the TB- PRACTECAL trial investiga-
tional regimens and their respective treatment outcomes?
Primary objective
Measure the plasma concentrations of pretomanid, 
linezolid, bedaquiline, Cfz and Mfx in a subset of patients 
in the TB- PRACTECAL trial and using population PK 
models, estimate the population exposure metrics (Cmin, 
Cmean, Cmax, area under the curve (AUC)) for the indi-
vidual drugs in the TB- PRACTECAL trial.
Secondary objectives
1. Develop PK models for each of the study drugs.
2. Develop a PKPD model to characterise the relation-
ship between drug exposure, baseline clinical covari-
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ates, baseline minimum inhibitory concentrations and 
early bactericidal effect.
3. Study correlations between baseline clinical covariates, 
baseline minimum inhibitory concentrations, drug 
exposure and longitudinal PKPKD markers and long- 
term treatment outcome defined as success at end of 
treatment and remaining relapse free for 1 year after 
successful treatment.
4. Develop PKPD models investigating associations be-
tween PK parameters and treatment emergent toxicity.
5. Use results from the aforementioned algorithms to de-
velop a hypothesis on the optimal dosing of linezolid 
and Cfz using Monte- Carlo simulations.
Patient and public involvement
Patients were not directly involved in the design of this 
study. However, the parent clinical trial engaged patients 
in the setup and implementation.25
Study setting
The study is recruiting and being implemented in five 
hospitals (figure 1) in Belarus and South Africa. The drug 
quantification bioanalysis will be conducted at the Univer-
sity of Liverpool, Liverpool, UK and the mycobacteri-
ology is done at Republican Specialised Practical Centre 
for Pulmonology and Tuberculosis National Reference 
Laboratory in Minsk for Belarus samples and Cytespace 
Africa laboratories in Pretoria, South Africa.
Study population
We are seeking to describe the population drug exposures 
and their variability in the target population, so a tradi-
tional power calculation was not done. The total number 
of patients recruited into the study is driven by the timing 
of starting the substudy and proportion of patients 
consenting. Based on the optimal design parameters, we 
aimed to recruit a maximum of 240 patients resulting 








Linezolid 1.86 1.96 16.6
Clofazimine 10 11.2 6.32
Pretomanid 7.71 4.16 2.02
Bedaquiline 2.78 2.84 6.08
Moxifloxacin 10.6 12.6 1.47*
*The moxifloxacin PK model used an informative prior from literature in the SSE.
PK, pharmacokinetic; RSE, relative SE; SSE, stochastic simulation and estimation.
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in just under 3000 drug concentration observations. We 
recruited 97 patients with an expected 1164 samples to be 
available for bioanalysis and at least 3492 drug concentra-
tion measurements for the four study drugs.
Inclusion/exclusion criteria
All adult patients recruited into the investigational arms 
of the parent TB- PRACTECAL trial in the approved sites 
are eligible to join the study (https:// clinicaltrials. gov/ 
ct2/ show/ NCT02589782) with the following eligibility 
criteria:
Inclusion criteria:
Patients eligible for inclusion in the trial must fulfil all 
of the following criteria:
 ► Male or female subjects aged 15 years of age or above, 
regardless of HIV status.
 ► Microbiological test (molecular or phenotypic) 
confirming presence of Mycobacterium tuberculosis.
 ► Resistant to at least rifampicin by either molecular or 
phenotypic drug susceptibility test.
 ► Completed informed consent form (ICF).
Exclusion criteria:
 ► Known allergies, hypersensitivity or intolerance to any 
of the study drugs.
 ► Pregnant or breast feeding; or unwilling to use appro-
priate contraceptive measures.
 ► Liver enzymes >3 times the upper limit of normal.
 ► Any condition (social or medical) which, in the 
opinion of the investigator, would make study partici-
pation unsafe.
 ► Taking any medications contraindicated with the 
medicines in the trial; QTcF >450 ms.
 ► One or more risk factors for QT prolongation 
(excluding age and gender) or other uncorrected risk 
factors for Torsades de Pointes.
 ► History of cardiac disease, syncopal episodes, sympto-
matic or asymptomatic arrhythmias (with the excep-
tion of sinus arrhythmia).
 ► Any baseline biochemical laboratory value consistent 
with grade 4 toxicity.
 ► Moribund.
 ► Known resistance to bedaquiline, pretomanid, dela-
manid or linezolid.
 ► Prior use of bedaquiline and/or pretomanid and/or 
linezolid and/or delamanid for one or more months.
 ► Patients not eligible to start a new course of MDR- TB 
or extensively drug resistant (XDR)- TB treatment 
according to local protocol, including but not limited 
to:
 – Currently on MDR- TB treatment for more than 2 
weeks (and not failing).
 – Unstable address.
 – Lost to follow- up in previous treatment with no 
change in circumstance and motivation.
 ► Tuberculous meningoencephalitis, brain abscesses, 
osteomyelitis or arthritis.
The additional criteria for inclusion into the 
PRACTECAL- PKPD study is for the patient to be aged 18 
years or older, to sign the sub- study ICF after agreeing to 
the additional blood draws.
STUDY OUTLINE
Study period
The first batch of samples’ bioanalysis will start in the 
second quarter of 2021 and continue at regular intervals 
on batched samples. The data cleaning and analysis will 
be continuous until end of study.
Study procedures
Patients undergoing recruitment into the 
TB- PRACTECAL trial will be systematically requested to 
join the PRACTECAL- PKPD study as well if eligible. After 
screening and randomisation, only patients who have 
been randomised to the investigational regimens will be 
available to be recruited into the PRACTECAL- PKPD.
At least 4 mL (vacutainer tube, lithium heparin) of 
blood will be collected from the hand, forearm or ante-
cubital vein at each sampling occasion and moment for 
the PK. The sampling occasions are on Day 1, Weeks 8, 
12, 16, 20, 24, 32 and 72 (figure 2). On day 1, blood will 
be collected just before drugs intake, then 2 and 23 hours 
after drugs intake. On week 8, blood will be collected 
just before drugs intake, then 6.5 and 23 hours postdose. 
These multiple blood sample occasions may require the 
patient to stay in hospital overnight. At weeks 12, 16, 
20 and 24 the blood will be collected just before taking 
the dose. Both the planned and actual blood collection 
times should be documented at the earliest opportunity. 
Samples from week 32 and 72 will be collected whenever 
feasible after the patients have completed their treatment 
so blood collection is not relative to drug intake on that 
occasion. These have been included to capture the elim-
ination phases of the drugs which have long terminal 
half- lives.
Collected PK blood samples will be centrifuged at 
1000 G for 5 min within 30 min of blood drawing, if 
this is not possible the sample will be refrigerated for 
a maximum of 60 min. The supernatant plasma will be 
aspirated and pipetted into two equal aliquots approx-
imately 1.5 mL each and stored in temperature of max 
−20°C within 60 min of collection, it should then be 
transferred to dry ice if transport is required and stored 
in a −80°C freezer. At defined intervals, these frozen 
samples will be shipped on dry ice to the University of 
Liverpool laboratory.
Bioanalytical plan
Individual drugs concentrations will be quantified in a 
Good Clinical Laboratory Practice compliant bioanalyt-
ical facility using validated liquid chromatography- tandem 
mass spectrometry assay methods. Assay performance, 
sample chromatograms, standard curves and the validity 
of methods will also be reported.
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Data collection
Demographic data will include age, sex and site. Data 
for safety outcomes will be collected as part of the main 
TB- PRACTECAL trial. These include triplicate ECGs at 
baseline, predose and at 4–6 hours postdose on day 7 and 
then weekly up to week 8. After week 8, triplicate ECGs 
predose only every 4 weeks up to week 24, every 8 weeks 
up to week 48 and then week 72. Full blood count, urea 
and electrolytes, liver function tests and lipase will be 
performed on day 0, weekly up to week 8 and monthly 
up to week 24, at weeks 32, 72 and 108. Audiometry and 
ophthalmological assessments are also conducted as per 
investigational schedule. These will be reported as serious 
adverse events (AE), AE of special interest and other 
AEs with their respective severity grading using the MSF 
Severity Grading Scale.26
Data for the assessment of efficacy outcomes will be 
collected as part of the main TB- PRACTECAL trial and 
include: sputum for smear, culture (time to positivity in 
MGIT) and MIC at baseline and monthly up to week 24 
then every 2 months to week 108. Weight and height at 
baseline then weight at every visit until completion. Chest 
X- ray at baseline and week 24.
Other relevant covariate data collected include history 
of TB treatment and baseline blood glucose levels.
PK-specific data collection
Study- specific electronic clinical report forms will include 
scheduled sample collection time, actual time sample 
taken, time separation completed, time stored at −20°C 
or lower, time last dose taken, prior exposure to drugs of 
interest, covariates such as time last meal taken, concom-
itant medications especially ARVs and the time of the last 
dose.
Data analysis
PK and PKPD models will be developed for each drug 
based on the plasma concentrations in the study. Nlme 
modelling software packages (eg, NONMEM or nlmixR) 
using first- order conditional estimation method with 
interaction (focei) will be used. Several combina-
tions of absorption models (first order, first order with 
lag- time and transit absorption), distribution models 
(one- compartment, two- compartment and three- 
compartment distribution), variability models (between- 
subject variability and between occasion variability), and 
error models (additive, proportional and combined 
additive and proportional error models) will be assessed. 
Relative oral bioavailability will be evaluated as a fixed 
parameter (100% for the population), to allow estima-
tion of the between- subject and between- occasion vari-
ability of the relative bioavailability. Competing models 
will be evaluated during the model building process by 
the objective function value (OFV—computed as minus 
twice the log likelihood of the data), physiological plau-
sibility, and goodness- of- fit diagnostics. A significant 
(p=0.05) improvement will be concluded if the OFV 
dropped with 3.84 points or more (after the introduction 
of one new parameter, that is, one degree of freedom). 
Effects of covariates on PK model parameter estimates 
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will be assessed using a stepwise covariate modelling 
approach. During the forward inclusions a p=0.05 will 
be considered a significant improvement of the model 
fit while during the backward eliminations a p=0.01 will 
be considered significant improvement of the model fit. 
Model evaluation will include residual plots and visual 
predictive checks.27 Prior information in a Bayesian 
framework will be applied where the venous plasma 
sampling design fails to support sufficient precision on 
PK parameter estimates.
Direct linear, EMAX and sigmoid EMAX models will be 
studied in order to characterise the concentration–effect 
relationship with a PKPD model. Effects of covariates on 
PKPD model parameters will be assessed, including the 
effects of relevant concomitant medications, using iden-
tical statistical criteria as described for the PK models 
in combination with physiological and pharmacological 
plausibility.
For adverse events both direct and delayed, that is, 
using an effect compartment, linear, EMAX and sigmoid 
EMAX models will be investigated to the concentration–
effect relationships.
Model development will start as soon as we have the 
samples from at least 60 patients analysed, that is, interim 
analysis. Structural models from the interim analysis will 
be re- evaluated and full covariate analyses will be done 
once the full dataset becomes available.
For dose optimisations, first, a virtual patient popula-
tion will be simulated on the basis of observed baseline 
characteristics among patients enrolled in the study. 
Then clinically feasible dosing scenarios will be formu-
lated. Lastly, Monte- Carlo simulations done in order to 
study PK, PKPD and toxicity endpoints following the 
various dosing scenarios.
REGULATORY AND ETHICAL CONSIDERATIONS
The study has been approved by the MSF Ethics Review 
Board (reference no. 1541) and the LSHTM Ethics 
Committee (reference no. 16249) from the two leading 
institutions. The Belarus RSPCPT ethics committee and 
the regulator- Centre of Excellence for the Minsk site. 
PharmaEthics for the Don Mckenzie and Dorris Goodwin 
hospitals sites, University of Witwatersrand Human 
Research ethics committee for the Helen Joseph and 
King DiniZulu Hospitals sites and the South Africa Health 
Products Regulatory Authority.
The informed consent process will be in line with 
International Council for Harmonisation of technical 
requirements for pharmaceuticals for human use (ICH) 
Good Clinical Practice guidance. The information given 
and informed consent process will be in the patient’s 
preferred language and documented on a written consent 
form signed by both the patient and investigator. Where 
the patient is illiterate, a thumb print of the participant as 
well as the signature of a witness independent of the study 
will be documented.
DISSEMINATION
The results of the study will be presented at scientific 
conferences and published in a peer- reviewed journal. 
If the TB- PRACTECAL trial successfully identifies effec-
tive and safe regimens, the results of this study may be 
used to inform a WHO guidelines process by potentially 
answering specific questions on recommended dosages 
of the B, Pa, Lzd- based regimens as well as potentially 
informing study countries decisions.
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